drugset / Trial / NCT01780077

Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109

NCT01780077 ↗

Phase 1 Completed 15 enrolled RXi Pharmaceuticals, Corp.
RandomizedSingle-groupTriple-blindTreatment

Summary

The purpose of this trial is to evaluate the safety and tolerability of multiple (3) intradermal doses of RXI-109 at small surgical incisions in the abdominal skin of healthy volunteers. The effect of RXI-109 versus placebo on scarring at these incision sites will be evaluated visually, histologically, and by biomarker analysis.

Timeline

Start
2012-12
Primary completion
2014-06
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Subject RXI-109 Unknown — Other

Indications

No indication recorded.